United States

People: Cempra Inc (CEMP.O)

CEMP.O on Nasdaq

21 Oct 2016
Change (% chg)

$0.21 (+0.88%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Fernandes, Prabhavathi 

Dr. Prabhavathi B. Fernandes, Ph.D., is President, Chief Executive Officer and Director of Cempra Inc. Dr. Fernandes, one of our founders, has been our President and Chief Executive Officer and a member of our board of directors since our founding in November 2005. Prior to that, she was President and Chief Executive Officer of several privately-held companies, including DarPharma, Inc. from 2003 to 2005, Ricerca Biosciences from 2000 to 2003 and Small Molecule Therapeutics from 1998 to 2000. Dr. Fernandes was Vice President, Drug Discovery of Bristol-Myers Squibb Company from 1988 to 1998, Senior Director of Squibb Pharmaceutical Research Institute from 1987 to 1988, Senior Project Leader of Abbott Laboratories from 1983 to 1987 and Senior Microbiologist of the Squibb Institute for Medical Research, the research division of E.R. Squibb and Sons, from 1980 to 1983. During her years at Squibb, Abbott and Bristol-Meyers Squibb, she was directly involved in the development of numerous antibiotics, four of which have been approved by the FDA and one achieving sales over a billion dollars. She has served on the advisory board of Optimer Pharmaceuticals, Inc. since 2004 and the supervisory board of GPC Biotech AG from 2004 to 2008. Dr. Fernandes served on the product development working group for Biodefense for the National Institute of Allergy and Infectious Diseases from 2003 to 2004 and the U.S. Congressional Panel for Assessment of Impact of Antibiotic Resistant Bacteria and the American Society for Microbiology Advisory Panel for Antibiotic Resistance from 1991 to 1995. Dr. Fernandes holds a B.S. in botany, zoology and chemistry from the University of Bangalore (India), an M.S. in microbiology from the Christian Medical College (India) and a Ph.D. in microbiology from Thomas Jefferson University, Philadelphia,

Basic Compensation

Total Annual Compensation, USD 680,112
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,641,440
Fiscal Year Total, USD 2,321,550

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Garheng Kong


Prabhavathi Fernandes


Mark Hahn


John Bluth


David Moore


David Oldach

As Of  30 Dec 2014